Online inquiry

IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11668MR)

This product GTTS-WQ11668MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11668MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2628MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ12991MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ3086MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ11869MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ6159MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ11300MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ6693MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ10944MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MBG-453
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW